Introduction by Gibbon, SE et al.
We finalize this book on the ‘time of BRCA’ at a pivotal moment in the history 
of breast cancer genetics. The BRCA genes are configured amidst dynamically 
interacting medical, scientific, cultural, socio-political and economic parameters, 
which are essential to understanding this continually evolving terrain.
Using BRCA as a case study, this book sheds light on transformations that are 
occurring in the wider field of genomic science and medicine as a result of new tech-
nological possibilities, transnational research collaborations and ever-widening 
parameters and definitions of risk. Our focus on time-economies illustrates how 
temporal notions of past, present and future are built into genomic developments, 
and as such facilitates a re-reading of core concepts like risk, prevention, kinship 
and heredity. We begin, however, by highlighting some key recent developments 
in the field of BRCA genetics that illustrate this shifting terrain.
The first and perhaps most highly anticipated development is the recent US 
Supreme Court decision regarding the patentability of genes. The two breast can-
cer genes BRCA1 and 2 were sequenced in the mid 1990s through the efforts of 
multiple international research teams, and shortly thereafter patented by one of 
the US teams managed by Mark H. Skolnick, co-founder of Myriad Genetics Inc. 
(Salt Lake City, US). Since then, debates about the commercialization of biologi-
cal knowledge and the proliferation of the ownership of genes have continued to 
be highly controversial. In June 2013, the US Supreme Court announced their 
decision to outlaw patents on naturally occurring genes (but not on cDNA) put-
ting an end to Myriad Genetics’ long-held and contentious monopoly on BRCA 
testing in the US (see van Zimmeren et al., this volume).1 Significantly, several 
companies that were already providing genetic testing of other genes associated 
with breast cancer were ready to launch their own BRCA tests the day after the 
decision was announced (e.g. see the Ambry press release the day of the Supreme 
Court Announcement, www.ambrygen.com/press). The defeat of Myriad’s patent 
monopoly could make genetic testing without threat of litigation more financially 
feasible and therefore a more widespread option, or lead to an increase in research 
by groups previously hindered by concerns about patent infringement. Of course, 
the ramifications of the court’s decision both inside and outside the US remain 
to be seen, and may take years to fully unfold while also having repercussions in 
global arenas.2
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Second, the emergence of Next Generation panel tests (e.g. Ambry Genetics’ 
BreastNext panel and the University of Washington’s BROCA panel), and the 
increasing turn towards whole genome/exome sequencing, signals another change 
in the landscape of genetic testing. Next Generation panel tests, which became com-
mercially available in 2011, examine numerous genetic changes associated with 
elevated breast cancer risk, including those that confer moderate and relatively low 
risk. As Next Generation testing becomes more widely available and financially fea-
sible (some of the panel tests cost approximately the same as or less than Myriad’s 
BRCA test), the criteria for testing related to hereditary breast cancer syndromes 
will likely widen. At the same time, the decreasing cost of whole exome/genome 
sequencing will likely have even broader implications, as in the future individuals 
may have their entire genomes sequenced rather than portions of it (such as the 
BRCA genes only). One potential consequence is that many more individuals will 
learn they carry a BRCA mutation (and many other disease-associated mutations) as 
a result of sequencing carried out for some other purpose – a scenario that is directly 
explored by Sandra Lee in this volume, in the context of BRCA testing in the direct-
to-consumer setting. While Next Generation panel tests and advanced sequencing 
technologies predate the recent Supreme Court decision on gene patents, they will 
likely be informed by this decision in complex ways, thereby paving the way for 
expanded and broader BRCA testing. This constantly changing technological land-
scape which now includes whole genome sequencing has exponentially increased 
the initial concerns raised by BRCA testing, such as those regarding privacy, inci-
dental findings, variants of unknown significance and return of results (Green et al. 
2013; Kohane, Masys, and Altman 2006, Pyeritz 2011).
Third, BRCA genetics has been and continues to be a test case in the field of 
genomic medicine (Gibbon et al. 2010b; Palfner 2009): a symbol of ‘success’ 
whilst also being at the forefront of challenging the new genetics. Nevertheless, 
in thinking about BRCA as a barometer for the shifting space and evolving trajec-
tory of predictive medicine, it is important to stress the gendered and gendering 
nature of these medical interventions that are aimed primarily at women (such as 
the prophylactic removal of breasts and ovaries; also see Pelters, this volume). 
Thus as BRCA evolves and spreads into new medical arenas, women continue to 
find themselves the subjects of increasing medical and scientific practices. These 
dynamics coexist with well-established medical practices aimed at women such as 
annual gynecological exams and mammographic screening programmes, and are 
entangled with deeply gendered life-worlds in which women function as ‘genetic 
housekeepers’ (Richards 1996: 261). Furthermore, if we consider BRCA genetics 
to be a test case in the field of genomic medicine, then women are the experimen-
tal field on which such endeavors are taking place (Gibbon forthcoming; Happe 
2006, 2013; Palfner 2009).
We can see the intersection of gender and genomics with the recent high-profile 
announcement by Hollywood star Angelina Jolie in a New York Times op-ed that 
she had undergone a preventive double mastectomy due to a ‘faulty’ BRCA1 gene, 
bringing BRCA genetics to international attention. Jolie’s decision was particu-
larly striking given her status as an international sex symbol, and contributed to 
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increased interest in testing among many women around the world. Indeed, those 
of us based in cancer centres can attest to ‘the Angelina effect’: the increased 
volume in calls and inquiries from members of the public following the announce-
ment. On the other hand, media debate, and the comments from readers of the New 
York Times and many other news outlets took up questions about access to the test 
and the recommended screening and prevention practices (Jolie’s announcement 
arrived just weeks prior to the Supreme Court’s decision on Myriad’s patents), 
and about the appropriateness of ‘proactive’ measures like the preventive double 
mastectomy surgery that Jolie had. Jolie’s announcement about her decision thus 
provoked polemical discussion about prevention and risk reduction, access to test-
ing, gene patents the options available to women identified at risk in this way, 
and in some cases, the right ‘not to know’ about genetic risk. Her announcement 
serves to both highlight the way that gendered idioms of female nurturance and 
empowerment continue to be central to this domain, and the ongoing impact of 
BRCA on women.
These developments and the recent intense media attention to BRCA that has 
resulted provide an opportune moment for us as social scientists to engage and 
explore the shape-shifting present and future terrain of BRCA genetics. The con-
fluence of events, while each of a different scale and magnitude, has heightened 
interest and attention to genetic testing for hereditary cancer and related mat-
ters. This book thus provides a timely contribution which reflects on the diverse 
socio-cultural spaces as well as the scientific and medical practices that constitute 
genomics in the era of BRCA.
BRCA histories
The identification of the BRCA genes in the mid 1990s was accompanied by an 
enormous amount of expectation, hype and hope, and swiftly led to the estab-
lishment of predictive genetic testing and specific medical programmes for those 
at high risk of developing breast cancer in many countries, particularly the US, 
Canada and Europe. Carriers of mutations in the BRCA genes are thought to 
have a higher risk of breast and ovarian cancer, although risk estimates vary from 
45–80 per cent for breast (compared to 10 per cent for an average woman) and 
10 to 60 per cent for ovarian cancer (compared to 1.8 per cent for an average 
woman). While they do not account for the majority of breast cancers, BRCA 
mutations are thought to be responsible for 5 to 10 per cent of breast cancers. 
Although BRCA1 and 2 have been primarily discussed in the context of familial 
breast and ovarian cancer, since their initial identification there has been a concur-
rent hope that the knowledge gained from BRCA research would have relevance 
for, and be transferable to, the treatment of sporadic breast cancers, which affect 
many more women than the rare instances of familial breast cancer (Palfner 2009). 
However the establishment of a robust connection between the clinical utility of 
BRCA and the sporadic cancer domain emerged only recently, in 2004–2005, 
when the concept of ‘BRCAness’ took hold, as discussed by Bourret and co-authors 
in this collection.
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Since their discovery, the medical institutionalization of BRCA knowledge-
practices and accompanying techniques for assessing risk have advanced at a rapid 
pace, involving different scientific or medical specialties, routinizing programmes 
of genetic testing, developing risk assessment for breast cancer and increasing 
health management options for those identified at increased cancer risk. The avail-
ability of BRCA samples obtained through programmes of genetic testing and 
risk assessment has facilitated further research (Gibbon et al. 2010b; Mozersky 
2013; Palfner 2009), illustrating the mutually constitutive interactions between 
BRCA research and clinical practices. The emergence and use of BRCA genetic 
knowledge in clinical settings has raised questions about the social consequences 
of genomic information for ‘patients’, family and their kin as well as the scientific 
and clinical utility of novel knowledge of genetic risk for breast cancer. Social 
scientists have studied these developments in different countries from diverse 
perspectives, which include: examining the historical dimensions of genetic 
research and the related medical practices or the laboratory life that surrounds 
novel techniques linked to BRCA genetics (Bourret, 2005; Löwy, 2010; Palfner, 
2009; Parthasarathy, 2007); analyzing the social consequences for health, iden-
tity and perceptions of risk for women undergoing assessment in cancer genetic 
clinics (Gibbon, 2007; Hallowell, 1999; zur Nieden, 2010, 2013) or comparing 
the cultural and institutional specificity of these developments, demonstrating the 
unevenness of the complex global intersections that are forming across a diverse 
field of genomic knowledge and technology (Gibbon et al. 2010a, Gibbon 2013; 
Mozersky and Joseph 2010; Shkedi-Rafid et al. 2012).
While the medical and laboratory practices surrounding the BRCA genes 
expand, their scientific and medical bases, on the other hand, continue to raise 
questions. In fact, very shortly after the sequencing of BRCA1 and 2, predictive 
genetic testing made it apparent that very few people actually carry the BRCA1 or 
BRCA2 mutations (5–10 per cent as previously mentioned), and many mutations 
were found in families without increased incidences of breast cancer. This vari-
ability in risk and penetrance estimates reflects gaps in medical knowledge about 
the BRCA genes which are based on databases of known mutations and previ-
ously identified ‘at risk’ families and/or populations. This variability has become 
increasingly apparent particularly in national contexts outside the US, Canada 
and Europe (see Mozersky and Gibbon, this volume), and highlights the role of 
nongenetic and epigenetic factors in determining risk.
At the same time, the BRCA genes have led to new avenues of medical research, 
particularly in the use of genetic technologies for the diagnosis and treatment of 
breast cancer (e.g. clinical trials of targeted drug therapies for BRCA mutation 
carriers; see also Section 3 in this volume) and raised questions concerning the 
medical management of female mutation carriers and women at high risk, such as 
the effectiveness of mammography, the benefits of tamoxifen in chemoprevention 
and prophylactic mastectomy. Thus this field of medical practice and scientific 
engagement continues to evolve, in part as a response to the limitations of BRCA 
genetic testing. In this sense, breast cancer genetics provides a vital arena for 
examining how scientific stability or transition is achieved in different contexts, 
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for example from lab to clinic or from BRCA genetics to other research arenas 
(e.g. epigenetics, ‘Next Generation’ panel testing and whole genome/exome 
sequencing). In other words, BRCA shifts and spreads in various directions far 
beyond the very limited medical programmes for familial breast and ovarian cancer.
Time-economies
As the title of this book and the chapters within indicate, we are living in the time 
of BRCA. In this sense, BRCA not only stimulates enormous research and pushes 
it in various directions; it also reconfigures the life-worlds of many women (and 
men), enhances specific medical programmes and puts economic, legal and ethical 
issues on the agenda of many health care systems. However, BRCA genes do not 
hold innate agency or power; rather as Palfner (2009), drawing on Haraway (1997) 
and Latour (2004) suggests, we should understand BRCA as an assemblage. For 
Haraway (1997: p. 142), ‘a gene is not a thing, much less a “master molecule” or 
a self-contained code but rather the term gene signifies a node of durable action 
where many actors, human and nonhuman, meet’. Latour (2004: p 233) underlines 
that the word thing also means ‘assembly’: ‘A thing is, in one sense, an object out 
there and, in another sense, an issue very much in there, at any rate, a gathering’. 
In terming the breast cancer gene an assemblage, we aim to heighten awareness of 
how it orchestrates and performs biomedical practices, stimulates socio-political 
discourses and connects various medical and research arenas through times and 
spaces, as the essays throughout this volume demonstrate.
Temporality is a theme that weaves through all three sections of the collection, 
from looking back at history and genealogy (Section I), to the ways in which risk 
is embodied and lived in the present (Section II), to the changing landscape and 
future developments of BRCA testing (Section III). While the principal aim of 
this book is to give an overview of BRCA research and medical practices in dif-
ferent countries, the contributing authors also analyze the theme of temporality as 
it emerges in the varied contexts they explore. The political scientist Wolf-Dieter 
Narr reminds us that time is a social product and intersects with relations of power: 
‘Ruling power is always characterized by its own calendar, its own hierarchy, 
its own assignment of time and its own quality of this assigned time, regardless 
of whether every ruling power, such as the brief rule of the Jacobins during the 
French Revolution, literally had their own calendar’ (2003: 239; author’s [SP] 
own translation). In other words, time itself is heterogeneous and performative, 
and we suggest that living in the time of BRCA should encourage us to take into 
account time itself and recognize that understanding time is a precondition for bet-
ter understanding the ongoing research and multiple medical practices related to 
BRCA. Thus, we think it is appropriate to speak about BRCA ‘time-economies’, 
seeing these as social matters and hence infused with power in different ways and 
making it vital to understand more deeply the interplay of various temporalities.
In the context of biomedicine, the matter of time materializes clearly in the 
notion of disease prevention. In her commentary (this volume), Martina Schlünder 
argues that the most important epistemic change from medicine to biomedicine is 
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the reconfiguration of the relation between the normal and the pathological with 
an increasing emphasis on health instead of disease (Clarke et al. 2010; Keat-
ing and Cambrosio 2003). The prevention of diseases is now seen as one of the 
most urgent tasks in medicine as opposed to limiting actions to the treatment of 
pathological events that have already happened (in an unalterable past) or are still 
ongoing in the present. According to Adams et al. (2009: 248), disease preven-
tion and predictive medicine are practices that occur in a mode of anticipation 
and the attempt to envision, control and manage the future and its risk of pos-
sible pathological events: ‘Crucially, the future increasingly not only defines the 
present but also creates material trajectories of life that unfold as anticipated by 
those speculative processes. Anticipation is rapidly reconfiguring technoscientific 
and biomedical practices as a totalizing orientation.’ Following this, we begin to 
understand the discursive power to name genes ‘breast cancer genes’. On the one 
hand, BRCA1 and 2 are understood as tumor suppressor genes, with a single germ 
line mutation increasing the risk for developing breast and/or ovarian cancer; such 
genes thus protect cells from one step on the path to cancer. On the other hand, 
to call a gene a ‘breast cancer gene’ implies the opposite, namely that this gene 
is responsible for the cancer and carrying the gene means having cancer. In other 
words, this overlap of the pathological and the normal rolls out through the antici-
pation of breast cancer in the gene.
This unfolding in the identification of ‘risk’ for breast and ovarian cancer via 
BRCA testing has resulted in the normalization of preventive procedures (Robson 
et al. 2010) such as prophylactic mastectomy and prophylactic oophorectomy (see 
Pelters and Gordon, this collection, for discussions of prophylactic mastectomy), 
chemoprevention as well as Preimplantation Genetic Diagnosis (PGD) to screen 
embryos at risk of carrying a BRCA mutation (Rubin and de Melo-Martin, this 
volume). Although the acceptance and use of these preventive measures varies 
significantly within and across national contexts, these practices must be situated 
within this biomedical maelstrom in which prospective diseases are pushed into 
the present and thereby have a major impact on present life-worlds including the 
meaning of patienthood and cancer survivorship (Bell 2013).
The increasing focus on prevention in biomedicine shows up in BRCA-related 
practices in other ways too. In some instances, the shift toward prevention is con-
stituted by a move toward wider screening for deleterious BRCA mutations in 
particular populations. For example, a recent study of African American women 
with breast cancer which found high rates of deleterious mutations in BRCA and 
other ‘breast cancer genes’ (e.g. CHEK2, PALB, PTEN) suggested screening for 
all these genes in women of African descent with breast cancer diagnosed at a 
young age, with a family history, or with triple negative breast cancer (Churpek 
et al. 2013). In both Israel and Canada, population-wide screening of all Ashke-
nazi Jews (regardless of family history) has been proposed as a viable method to 
identify BRCA carriers who might not otherwise come to clinical attention (Levy-
Lahad et al. 2011; Metcalfe et al. 2009). On another track, public health scientists 
and practitioners in the US are making efforts to identify potential BRCA carriers 
prior to a diagnosis by screening – in both clinical and community settings – for 
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family history and appropriate referrals to genetic counseling (rather than genetic 
testing) for a full assessment of BRCA risk (e.g. Bellcross et al. 2009; Joseph 2012 
and this volume). Thus the categories of who is at risk continue to encompass 
more and more people, in the name of prevention, as does the notion of being at 
risk for breast cancer itself.3 In other words, the enormous potential for BRCA 
research to be applied to a wide range of arenas of medical research and treatment 
and to incorporate different clinical disciplines has made and continues to make 
BRCA genetics significant.
The shift toward prevention also reflects breast cancer activists’ and research-
ers’ increasing attention to the causes of breast cancer rather than only treatment 
and survivorship. While some argue that treatment for breast cancer has improved 
over recent decades in terms of the survivorship rates, others suggest this is due to 
overdiagnosis (e.g. Esserman et al. 2013). Most agree, however, that the treatments 
themselves remain terribly damaging with enormous side effects. As a result, the 
goal of preventing breast cancer in the first place has become more prominent in 
certain national contexts. In addition, the failure to identify the causes of breast 
cancer to date, particularly the environmental factors that contribute and may 
intersect with hereditary susceptibility, is recognized as a huge barrier to reduc-
ing morbidity and mortality due to breast cancer – and as a failure of the research 
community. The politics of environmental pollution and the lack of regulation of 
polluters has also become a target for activists, particularly in the US, who have 
shifted their focus to prevention as discussed by Kirsten McHenry in her paper at 
the Brocher Conference where this volume originated (not included in this vol-
ume; see also BreastCancerAction.org).4 While epigenetic research holds out the 
promise that the parameters of research related to prevention of breast cancer may 
eventually encompass a more biopolitical framework that addresses collective 
responsibilities for disease and health, this is unlikely to mean the disappearance 
of individualized framings of risk. As Landecker and Panofsky (2013) point out, 
this may in fact paradoxically entail an intensification of the moral framing of 
gendered health responsibilities given that the ‘critical windows’ at stake in epi-
genetic research often relate to nutrition in early childhood and maternal-fetal 
health exposures (see also Mansfield 2012).
Transnational perspectives
By offering perspectives on the transnational arenas in which BRCA genetics is 
now evolving, this collection directly responds to the vital need for social sci-
ence to engage with genomics in the context of globalizing health care agendas 
and local moral worlds of practice. Some of the chapters directly take up the 
task of providing a comparative perspective with reflections on the way that for 
instance the so called ‘Ashkenazi mutations’ associated with the BRCA genes are 
being configured differently in Brazil and the UK (Mozersky and Gibbon) and 
in Germany (zur Nieden). The varying ways that questions of race and ethnic-
ity are being drawn into the developments surrounding breast cancer genetics 
are also highlighted in the contrasting perspective on these issues provided by 
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papers reflecting how different national histories concerning the politics of inclu-
sion and discrimination play out in Germany (zur Nieden) and the US (Joseph). 
For example, in Germany, the history of racial hygiene and the Holocaust as well 
as a specific tradition of perceiving the nation as ‘ethnically homogenous’ con-
tinue to have an effect on contemporary medical discourse. In the US, historical 
and ongoing discrimination experienced by African Americans affect how risk 
of genetic breast cancer and interventions may be viewed. Other chapters in this 
volume provide a reflection on the space which BRCA occupies, or rather does 
not occupy in contexts such as India (Macdonald) and Italy (Gordon), provid-
ing an important reminder of the ‘absent spaces’ that BRCA also constitutes. In 
Alison Macdonald’s discussion, we see how this absence relates to overwhelming 
socio-economic challenges and lack of resources in treating those with breast can-
cer, but also very specific beliefs about disease risk and its transmission between 
gendered bodies, as well as ‘biomoral’ concerns around family relations. Deborah 
Gordon similarly reminds us of the way a comparative perspective can illuminate 
the diverse routes through which BRCA has emerged. Gordon highlights how dis-
courses of disease risk related to BRCA genetics and the temporal anxieties they 
have provoked elsewhere (especially the US) have not resonated in Italy where 
different cultural logics of ‘risk’ are at play. This is reflected, for example, in the 
limited institutionalization of some BRCA medical practices such as prophylactic 
mastectomy in the Italian context.
At our Brocher workshop, we were fortunate to have participants who offered 
further contrasting reflections on the way that BRCA research and medical practices 
were evolving in Greece, Israel and Uruguay, providing additional illuminating 
and invaluable perspectives not present in this volume. Eirini Kampriani’s work 
in Greece has been and continues to be central to discussions in the BRCA group 
(see Kampriani 2009). Her presentation at the Brocher meeting showed the com-
plex ways that religious philanthropy and gendered ideologies have been a key 
dimension of BRCA medicine in Greece against a backdrop of limited and finite 
public health resources – an issue that is also addressed in a number of papers in 
the collection concerning BRCA genetics in India (Macdonald) and Brazil (Moz-
ersky and Gibbon). Shiri Shkedi-Rafid provided fascinating perspectives on the 
field of BRCA in Israel where the prospect of identifying BRCA carriers through 
population screening of Ashkenazi Jewish individuals without a family history is 
emerging as a viable avenue of intervention. Her work on the meaning of ‘carrier-
ness’ for those identified in this way has important implications, particularly given 
the expanded possibilities of Next Generation sequencing for identifying indi-
viduals with BRCA mutations without a significant family history (Shkedi-Rafid 
et al. 2012). Finally, Ana Egana’s work as part of a transnational collaborative 
initiative in Uruguay examined the relationship between ancestry and breast can-
cer. She highlighted the extent to which, for participants and also local researchers 
in Uruguay, socio-economic factors rather than ancestry per se were as important 
if not sometimes more relevant in perceptions of disease risk, raising important 
challenges to the homogenizing potential of global research paradigms, an issue 
that is also discussed by Mozersky and Gibbon.
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Challenges of being engaged/positioned/situated in  
our research fields
In the course of our discussions at Brocher, one of the themes that recurred was 
our own embeddedness in the medical and scientific field of BRCA genetics. As 
social scientists analyzing, engaging and sometimes even collaborating with what 
has become a multi-million-dollar industry that is now expanding across a global 
terrain of medical practice and scientific research, there is an awareness (for some 
uncomfortably so) that our own research trajectories have been informed (and in 
many cases funded) because of the high public profile that BRCA genetics con-
tinues to garner. As Haraway (1988: 581) pointed out, there is of course no view 
‘from nowhere’ and we are all necessarily ‘situated’ by working in the domain 
of BRCA genetics, whether we carry out research at the clinical interface, in the 
laboratory or with patient or activist populations. Entering and acknowledging the 
complexity of our situatedness in the context of interdisciplinarity or collaborative 
research is part of the challenging task of social scientists examining developments 
in the life and medical sciences, and one that others have begun to address. Prain-
sack and colleagues (2010) note the ever-present ambiguity of conducting social 
science research in such settings, highlighting the challenges of creating the space 
for critical social science perspectives and negotiating differences in authority and 
the legitimacy of contrasting methodological approaches. Barry et al. (2008) sug-
gest the need for a more complex understanding of interdisciplinarity and stress 
that interdisciplinarity has diverse histories and can take a multiplicity of forms. 
They interrogate how different modes of interdisciplinarity come into play and 
intersect, and raise valuable questions about the conditions under which particular 
styles of interdisciplinary practices appear and the ways they inform the outcomes 
of scientific knowledge production.5 Drawing on their approaches and reflecting 
on our own embeddedness as social science researchers in the field of BRCA 
genetics the following questions emerge: When – or even – is it possible to reach 
a synthesis of natural scientific and social scientific knowledge? Under which 
conditions does our own social science research function in a ‘service-mode’ to 
facilitate the research goals of the life and medical sciences? And how can the 
existing disciplinary epistemological and ontological assumptions be contested in 
such interdisciplinary collaborations? While these issues are implicit in many of 
the chapters presented, the questions raised about the ethics and politics of doing 
social science research at the interface with BRCA genetic research remain ongo-
ing challenges that are of central interest to a number of the book’s contributors, 
and which we suggest are crucial to social science research more generally in the 
field of genomic science and medicine, beyond BRCA.
* * *
The book is organized across three sections interspersed with a foreword from 
Rayna Rapp, commentaries from Nina Hallowell and Martina Schlünder and an 
afterword from Susanne Bauer, all of whom who we were fortunate to have in 
attendance at the Brocher workshop. The first section, ‘Practices of population 
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politics and history in the production of BRCA’, brings together three papers 
that place concerns with temporal pasts and presents centre stage. Collectively 
these papers tease out some of the complex questions concerning genetic research 
and categories of race/ethnicity and populations in the context of BRCA genetic 
research and medical interventions in different national contexts and/or for vari-
ous ‘under-served’ populations. The second section, entitled ‘Risk, personhood 
and subjectivity’, provides the framework for three papers that consider core 
issues of politics, gender and identity in the way that BRCA research and medical 
practice is enacted, whilst also importantly revealing the spaces where it is absent 
or resisted. The third section of the book, ‘Shifting terrains of BRCA knowledge 
and practices’, brings into view the emerging horizons of this dynamic domain of 
genetic research as it becomes incorporated into direct to consumer testing, trans-
lational research and pre-implantation diagnosis and is informed and potentially 
transformed by the recent decision in the US on the patentability of genes.
Notes
 1. cDNA is complementary DNA and refers to a form of DNA that is artificially 
synthesized.
 2. Within weeks of the Supreme Court decision, Myriad sued two competitors 
(Ambry Genetics and Gene by Gene), who began offering BRCA testing claim-
ing violation of some of their remaining patents not invalidated by the Supreme 
Court (New York Times, July 10, 2013, www.nytimes.com/2013/07/11/business/2-
competitors-sued-by-genetics-company-for-patent-infringement.html). At the 
same time, Myriad has pledged that it ‘will not impede non-commercial, academic 
research that uses patented technology licensed or owned by us’. (www.myriad.
com/responsibility/myriads-pledge/)
 3. See for instance the new UK NICE guidance on the preventative use of Tamoxifen 
or raloxifene for those with a family history of breast cancer as part of a strategy 
of chemoprevention. The same guidelines have suggested reducing the threshold 
for BRCA genetic testing for women from 20 per cent chance of having a BRCA 
gene mutation to 10 per cent, greatly widening the number of women eligible for 
genetic testing in the UK (www.nice.org.uk/newsroom/news/MoreTreatmentOptions 
WomenRiskBreastCancer.jsp)
 4. See Preface.
 5. Barry et al. 2008 suggest three difference interdisciplinary modes – integrative-
synthesis mode, subordination-service mode and agonistic-antagonistic mode.
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